Genetic Technologies (GTG) is collaborating with Obstetrics and Gynaecology practice Siles Health to implement the geneType Multi-Risk Test.

The geneType Multi-Risk Test has been designed to identify an individual’s risk of developing various common serious diseases.

It identifies the sporadic (non-inherited) risk that accounts for up to 85% of diagnosed cases of diseases that include ovarian cancer, type 2 diabetes, prostate cancer, colorectal cancer, breast cancer and coronary artery disease.

Knowing the risk of developing a disease allows the patient and their healthcare provider to put together a personalised preventive health plan.

As part of the collaboration, the geneType Multi-Risk Test will be implemented in nine Obstetrics and Gynaecology clinics belonging to Siles Health, a company that treats more than 15,000 patients each year.

GTG CEO Simon Morriss said: “Adoption of geneType Multi-Risk Test by Siles Health provides GTG with immediate access to an important and expanding group of patients, with the opportunity to make a significant improvement in their health outcomes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This partnership also represents another significant milestone along our pathway, the successful commercialisation of geneType Multi-Risk Tests.”

Siles Health will provide a dedicated in-house genetic counselling service to create personalised preventative pathways for patients that are identified as having a high risk of developing a disease.

The company will also refer patients to physicians that can provide dedicated genetic counselling support.

Siles Health founder Charles Siles said: “geneType Multi-Risk Test is a critical risk identification tool to assist our practice to identify potentially high-risk patients and develop truly actionable, personalised, preventative health plans.”

GTG stated that the partnership deal provides a framework for establishing a consistent standard of care for physicians and patients for the test.